<?xml version = '1.0' encoding = 'UTF-8'?>
<?xml-stylesheet href="/rss/styledrssBMC.css" type="text/css"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:extra="http://www.biomedcentral.com/xml/schemas/extra/" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/" xmlns:cc="http://web.resource.org/cc/">
	<channel rdf:about="http://www.biomedcentral.com/rss">
		<extra:info rdf:parseType="Literal">
			<html:div xmlns:html="http://www.w3.org/1999/xhtml" style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif">
				<html:span style="font-weight:bold">This is an RSS newsfeed from BioMed Central</html:span>
				<html:br/>
				<html:span style="font-size: 12px;">It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit <html:br/><html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">http://www.biomedcentral.com/info/about/rss/</html:a><html:br/>
				</html:span>
			</html:div>
		</extra:info>
		<title>BMC Gastroenterology - Most viewed articles</title>
		<link>http://www.biomedcentral.com/bmcgastroenterol/mostviewed/</link>
		<description>Most viewed articles in last 30 days from BMC Gastroenterology (ISSN 1471-230X) published by 
				
				BioMed Central
		</description>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
         <items>
            <rdf:Seq>
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-230X/7/46"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-230X/8/20"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-230X/7/34"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-230X/8/23"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-230X/8/21"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-230X/3/16"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-230X/3/18"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-230X/2/2"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-230X/8/24"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-230X/8/7"/>			    
            
            </rdf:Seq>
        </items>
    </channel>
    
		<item rdf:about="http://www.biomedcentral.com/1471-230X/7/46">
            
            <title>Effect of apple cider vinegar on delayed gastric emptying in patients with type 1 diabetes mellitus: a pilot study</title>
			<description>Background:
Previous studies on healthy people show that vinegar delays gastric emptying and lowers postprandial blood glucose and insulin levels. The aim of this study was to investigate the effect of apple cider vinegar on delayed gastric emptying rate on diabetes mellitus patients.
Methods:
Ten patients with type 1 diabetes and diabetic gastroparesis, including one patient who had undergone vagotomy, were included and completed the investigator blinded crossover trial. The gastric emptying rate (GER) was measured using standardized real-time ultrasonography. The GER was calculated as the percentage change in the antral cross-sectional area 15 and 90 minutes after ingestion of 300 g rice pudding and 200 ml water (GER1), or 300 g rice pudding and 200 ml water with 30 ml apple cider vinegar (GER2). The subjects drank 200 ml water daily before breakfast one week before the measurement of GER1. The same subjects drank 200 ml water with 30 ml vinegar daily before breakfast for two weeks before the measurement of GER2.
Results:
The median values of GER1 and GER2 were 27% and 17%, respectively. The effect of vinegar on the rate of gastric emptying was statistically significant (p &lt; 0.05).
Conclusion:
This study shows that vinegar affects insulin-dependent diabetes mellitus patients with diabetic gastroparesis by reducing the gastric emptying rate even further, and this might be a disadvantage regarding to their glycaemic control.Trial registration numberISRCTN33841495.</description>
			<link>http://www.biomedcentral.com/1471-230X/7/46</link>		
			<dc:creator>Joanna Hlebowicz, Gassan Darwiche, Ola Bj&#246;rgell and Lars-Olof Alm&#233;r</dc:creator>
			<dc:source>BMC Gastroenterology 2007, 7:46</dc:source>
			<dc:subject>Number of accesses: 1122</dc:subject>
			<dc:date>2007-12-20</dc:date>
			<dc:identifier>doi:10.1186/1471-230X-7-46</dc:identifier>
			
			
							
					<prism:publicationName>BMC Gastroenterology</prism:publicationName>
					
			
							
					<prism:issn>1471-230X</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>46</prism:startingPage>
					
			
							
					<prism:publicationDate>2007-12-20</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-230X/8/20">
            
            <title>Short-term triple therapy with azithromycin for Helicobacter pylori eradication: Low cost, high compliance, but low efficacy</title>
			<description>Background:
The Brazilian consensus recommends a short-term treatment course with clarithromycin, amoxicillin and proton-pump inhibitor for the eradication of Helicobacter pylori (H. pylori). This treatment course has good efficacy, but cannot be afforded by a large part of the population. Azithromycin, amoxicillin and omeprazole are subsidized, for several aims, by the Brazilian federal government. Therefore, a short-term treatment course that uses these drugs is a low-cost one, but its efficacy regarding the bacterium eradication is yet to be demonstrated. The study's purpose was to verify the efficacy of H. pylori eradication in infected patients who presented peptic ulcer disease, using the association of azithromycin, amoxicillin and omeprazole.
Methods:
Sixty patients with peptic ulcer diagnosed by upper digestive endoscopy and H. pylori infection documented by rapid urease test, histological analysis and urea breath test were treated for six days with a combination of azithromycin 500 mg and omeprazole 20 mg, in a single daily dose, associated with amoxicillin 500 mg 3 times a day. The eradication control was carried out 12 weeks after the treatment by means of the same diagnostic tests. The eradication rates were calculated with 95% confidence interval.
Results:
The eradication rate was 38% per intention to treat and 41% per protocol. Few adverse effects were observed and treatment compliance was high.
Conclusion:
Despite its low cost and high compliance, the low eradication rate does not allow the recommendation of the triple therapy with azithromycin as an adequate treatment for H. pylori infection.</description>
			<link>http://www.biomedcentral.com/1471-230X/8/20</link>		
			<dc:creator>Fernando M Silva, Jaime N Eisig, Ana Cristina S Teixeira, Ricardo C Barbuti, Tom&#225;s Navarro-Rodriguez and Rejane Mattar</dc:creator>
			<dc:source>BMC Gastroenterology 2008, 8:20</dc:source>
			<dc:subject>Number of accesses: 845</dc:subject>
			<dc:date>2008-05-29</dc:date>
			<dc:identifier>doi:10.1186/1471-230X-8-20</dc:identifier>
			
			
							
					<prism:publicationName>BMC Gastroenterology</prism:publicationName>
					
			
							
					<prism:issn>1471-230X</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>20</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-05-29</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-230X/7/34">
            
            <title>Portal vein thrombosis; risk factors, clinical presentation and treatment</title>
			<description>Background:
Portal vein thrombosis (PVT) is increasingly frequently being diagnosed, but systematic descriptions of the natural history and clinical handling of the condition are sparse. The aim of this retrospective study was to describe risk factors, clinical presentation, complications and treatment of portal vein thrombosis in a single-centre.
Methods:
Sixty-seven patients were identified in the electronic records from 1992 to 2005. All data were obtained from the patient records.
Results:
One or more risk factors (e.g. prothrombotic disorder or abdominal inflammation) were present in 87%. Symptoms were abdominalia, splenomegaly, fever, ascites, haematemesis, and weight loss. Abdominalia and fever occurred more frequently in patients with acute PVT. Frequent complications were splenomegaly, oesophageal- and gastric varices with or without bleeding, portal hypertensive gastropathy and ascites. Varices and bleeding were more frequent in patients with chronic PVT. Patients who received anticoagulant therapy more frequently achieved partial/complete recanalization. Patients with varices who were treated endoscopically in combination with &#946;-blockade had regression of the varices. The overall mortality was 13% in one year, and was dependent on underlying causes.
Conclusion:
Most patients had a combination of local and systemic risk factors for PVT. We observed that partial/complete recanalization was more frequent in patients treated with anticoagulation therapy, and that regression of varices was more pronounced in patients who where treated with active endoscopy combined with pharmacological treatment.</description>
			<link>http://www.biomedcentral.com/1471-230X/7/34</link>		
			<dc:creator>Kirstine K Sogaard, Lone B Astrup, Hendrik Vilstrup and Henning Gronbaek</dc:creator>
			<dc:source>BMC Gastroenterology 2007, 7:34</dc:source>
			<dc:subject>Number of accesses: 597</dc:subject>
			<dc:date>2007-08-15</dc:date>
			<dc:identifier>doi:10.1186/1471-230X-7-34</dc:identifier>
			
			
							
					<prism:publicationName>BMC Gastroenterology</prism:publicationName>
					
			
							
					<prism:issn>1471-230X</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>34</prism:startingPage>
					
			
							
					<prism:publicationDate>2007-08-15</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-230X/8/23">
            
            <title>Symptoms of gastroesophageal reflux disease in severely mentally retarded people: a systematic review</title>
			<description>Background:
Gastroesophageal reflux disease (GERD) occurs when stomach acid frequently backs up (or refluxes) into the gullet (or esophagus), and it has serious consequences for the quality of life. Usually this is felt as heartburn. Because severely mentally retarded people usually do not utter complaints of heartburn, it requires a high index of suspicion to discover possible GERD. Therefore it is relevant for care professionals such as nurses to have knowledge of those with a higher risk of GERD and of the possible manifestations of GERD.
Methods:
Using a predefined search method, electronic databases were searched for studies relating the presence of symptoms to the presence of GERD. Relevant data were extracted and the methodological quality of the studies assessed. The results of the included studies were synthesized and conclusions about the level of evidence were drawn.
Results:
Nineteen studies were found relating symptoms to the presence of GERD. Only four were of good methodological quality. The studies were very diverse concerning the studied population, the study method, and the kind of symptoms examined. This makes it difficult to synthesize the results of the studies. There is evidence that patients with cerebral palsy, patients using anticonvulsive drugs, and those with an IQ lower than 35 more frequently have GERD. There is also evidence that vomiting, rumination and hematemesis are associated with a higher risk of the presence of GERD, whereas there is no clear scientific evidence that particular behavior symptoms are indicative for GERD.
Conclusion:
The possible manifestations of GERD are many and varied. A guideline will be made for care professionals to aid systematic observation of possible manifestations of GERD.</description>
			<link>http://www.biomedcentral.com/1471-230X/8/23</link>		
			<dc:creator>Anke JE de Veer, Judith T Bos, Riet C Niezen-de Boer, Clarisse JM B&#246;hmer and Anneke L Francke</dc:creator>
			<dc:source>BMC Gastroenterology 2008, 8:23</dc:source>
			<dc:subject>Number of accesses: 536</dc:subject>
			<dc:date>2008-06-11</dc:date>
			<dc:identifier>doi:10.1186/1471-230X-8-23</dc:identifier>
			
			
							
					<prism:publicationName>BMC Gastroenterology</prism:publicationName>
					
			
							
					<prism:issn>1471-230X</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>23</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-06-11</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-230X/8/21">
            
            <title>Changes in the gastric enteric nervous system and muscle: A case report on two patients with diabetic gastroparesis</title>
			<description>Background:
The pathophysiological basis of diabetic gastroparesis is poorly understood, in large part due to the almost complete lack of data on neuropathological and molecular changes in the stomachs of patients. Experimental models indicate various lesions affecting the vagus, muscle, enteric neurons, interstitial cells of Cajal (ICC) or other cellular components. The aim of this study was to use modern analytical methods to determine morphological and molecular changes in the gastric wall in patients with diabetic gastroparesis.
Methods:
Full thickness gastric biopsies were obtained laparoscopically from two gastroparetic patients undergoing surgical intervention and from disease-free areas of control subjects undergoing other forms of gastric surgery. Samples were processed for histological and immunohistochemical examination.
Results:
Although both patients had severe refractory symptoms with malnutrition, requiring the placement of a gastric stimulator, one of them had no significant abnormalities as compared with controls. This patient had an abrupt onset of symptoms with a relatively short duration of diabetes that was well controlled. By contrast, the other patient had long standing brittle and poorly controlled diabetes with numerous episodes of diabetic ketoacidosis and frequent hypoglycemic episodes. Histological examination in this patient revealed increased fibrosis in the muscle layers as well as significantly fewer nerve fibers and myenteric neurons as assessed by PGP9.5 staining. Further, significant reduction was seen in staining for neuronal nitric oxide synthase, heme oxygenase-2, tyrosine hydroxylase as well as for c-KIT.
Conclusion:
We conclude that poor metabolic control is associated with significant pathological changes in the gastric wall that affect all major components including muscle, neurons and ICC. Severe symptoms can occur in the absence of these changes, however and may reflect vagal, central or hormonal influences. Gastroparesis is therefore likely to be a heterogeneous disorder. Careful molecular and pathological analysis may allow more precise phenotypic differentiation and shed insight into the underlying mechanisms as well as identify novel therapeutic targets.</description>
			<link>http://www.biomedcentral.com/1471-230X/8/21</link>		
			<dc:creator>Pankaj J Pasricha, Nonko D Pehlivanov, Guillermo Gomez, Harsha Vittal, Matthew S Lurken and Gianrico Farrugia</dc:creator>
			<dc:source>BMC Gastroenterology 2008, 8:21</dc:source>
			<dc:subject>Number of accesses: 473</dc:subject>
			<dc:date>2008-05-30</dc:date>
			<dc:identifier>doi:10.1186/1471-230X-8-21</dc:identifier>
			
			
							
					<prism:publicationName>BMC Gastroenterology</prism:publicationName>
					
			
							
					<prism:issn>1471-230X</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>21</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-05-30</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-230X/3/16">
            
            <title>Antral hyperplastic polyp causing intermittent gastric outlet obstruction: Case report</title>
			<description>Background:
Hyperplastic polyps are the most common polypoid lesions of the stomach. Rarely, they cause gastric outlet obstruction by prolapsing through the pyloric channel, when they arise in the prepyloric antrum.Case presentationA 62-year-old woman presented with intermittent nausea and vomiting of 4 months duration. Upper gastrointestinal endoscopy revealed a 30 mm prepyloric sessile polyp causing intermittent gastric outlet obstruction. Following submucosal injection of diluted adrenaline solution, the polyp was removed with a snare. Multiple biopsies were taken from the greater curvature of the antrum and the corpus. Rapid urease test for Helicobacter pylori yielded a negative result. Histopathologic examination showed a hyperplastic polyp without any evidence of malignancy. Biopsies of the antrum and the corpus revealed gastritis with neither atrophic changes nor Helicobacter pylori infection. Follow-up endoscopy after a 12-week course of proton pomp inhibitor therapy showed a complete healing without any remnant tissue at the polypectomy site. The patient has been symptom-free during 8 months of follow-up.
Conclusions:
Symptomatic gastric polyps should be removed preferentially when they are detected at the initial diagnostic endoscopy. Polypectomy not only provides tissue to determine the exact histopathologic type of the polyp, but also achieves radical treatment.</description>
			<link>http://www.biomedcentral.com/1471-230X/3/16</link>		
			<dc:creator>Rasim Gencosmanoglu, Ebru Sen-Oran, Ozlem Kurtkaya-Yapicier and Nurdan Tozun</dc:creator>
			<dc:source>BMC Gastroenterology 2003, 3:16</dc:source>
			<dc:subject>Number of accesses: 457</dc:subject>
			<dc:date>2003-06-27</dc:date>
			<dc:identifier>doi:10.1186/1471-230X-3-16</dc:identifier>
			
			
							
					<prism:publicationName>BMC Gastroenterology</prism:publicationName>
					
			
							
					<prism:issn>1471-230X</prism:issn>
					
			
							
					<prism:volume>3</prism:volume>
					
			
							
					<prism:startingPage>16</prism:startingPage>
					
			
							
					<prism:publicationDate>2003-06-27</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-230X/3/18">
            
            <title>A case of sigmoid endometriosis difficult to differentiate from colon cancer</title>
			<description>Background:
Although endometriosis with sigmoid serosal involvement is not uncommon in women of childbearing age, the mucosal involvement is rare and differential diagnosis from colon cancer may be difficult due to the lack of pathognomonic symptoms and the poor diagnostic yield of colonoscopy and colonic biopsies.Case presentationWe present a case of a young woman with sigmoid endometriosis, in which the initial diagnostic workup suggested colon cancer. Histologic evidence, obtained from a second colonoscopy, along with pelvic ultrasound findings led to the final diagnosis of intestinal endometriosis which was confirmed by laparoscopy.
Conclusion:
Colonic endometriosis is often a diagnostic challenge and should be considered in young women with symptoms from the lower gastrointestinal tract.</description>
			<link>http://www.biomedcentral.com/1471-230X/3/18</link>		
			<dc:creator>Philippos Dimoulios, Ioannis E Koutroubakis, Maria Tzardi, Pavlos Antoniou, Ioannis M Matalliotakis and Elias A Kouroumalis</dc:creator>
			<dc:source>BMC Gastroenterology 2003, 3:18</dc:source>
			<dc:subject>Number of accesses: 450</dc:subject>
			<dc:date>2003-08-07</dc:date>
			<dc:identifier>doi:10.1186/1471-230X-3-18</dc:identifier>
			
			
							
					<prism:publicationName>BMC Gastroenterology</prism:publicationName>
					
			
							
					<prism:issn>1471-230X</prism:issn>
					
			
							
					<prism:volume>3</prism:volume>
					
			
							
					<prism:startingPage>18</prism:startingPage>
					
			
							
					<prism:publicationDate>2003-08-07</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-230X/2/2">
            
            <title>Utility of the Mayo End-Stage Liver Disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis</title>
			<description>Background:
Alcoholic hepatitis is characterized by acute, or acute-on-chronic hepatic failure and associated with a high mortality. Specific therapies should be considered for those at high risk of mortality. The Mayo End-Stage Liver Disease (MELD) score is a marker of disease severity and mortality in persons with chronic alcoholic liver disease. Our aims were to assess the utility of the MELD score as a predictor of short-term mortality in persons with alcoholic hepatitis.
Methods:
We assessed the utility of the MELD score and compared it with the Discriminant Function (DF) as a predictor of mortality in 34 patients hospitalized with alcoholic hepatitis.
Results:
The area under the curve of a receiver operating characteristic curve for the MELD score was 0.82 (confidence intervals 0.65&#8211;0.98), and for the DF was 0.86 (confidence intervals 0.70&#8211;1.00). However, the sensitivity and specificity in predicting 30-day mortality for a MELD score of greater than 11 was 86% and 81%, but for a DF greater than 32 was 86% and 48% respectively. The presence of ascites and bilirubin greater than 8 mg/dL were also highly predictive of mortality with a sensitivity of 71% and a specificity of 96%.
Conclusions:
Alcoholic hepatitis remains associated with a high mortality in hospitalized patients. The MELD score performs as well as the DF in predicting mortality at 30 days. A MELD score of greater than 11, or the presence of both ascites and an elevated bilirubin greater than 8 mg/dL should prompt consideration of specific therapeutic interventions to reduce mortality.</description>
			<link>http://www.biomedcentral.com/1471-230X/2/2</link>		
			<dc:creator>Milan Sheth, Mark Riggs and Tushar Patel</dc:creator>
			<dc:source>BMC Gastroenterology 2002, 2:2</dc:source>
			<dc:subject>Number of accesses: 407</dc:subject>
			<dc:date>2002-01-22</dc:date>
			<dc:identifier>doi:10.1186/1471-230X-2-2</dc:identifier>
			
			
							
					<prism:publicationName>BMC Gastroenterology</prism:publicationName>
					
			
							
					<prism:issn>1471-230X</prism:issn>
					
			
							
					<prism:volume>2</prism:volume>
					
			
							
					<prism:startingPage>2</prism:startingPage>
					
			
							
					<prism:publicationDate>2002-01-22</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-230X/8/24">
            
            <title>The pro-apoptotic K-Ras 4A proto-oncoprotein does not affect tumorigenesis in the ApcMin/+ mouse small intestine</title>
			<description>Background:
Alterations in gene splicing occur in human sporadic colorectal cancer (CRC) and may contribute to tumour progression. The K-ras proto-oncogene encodes two splice variants, K-ras 4A and 4B, and K-ras activating mutations which jointly affect both isoforms are prevalent in CRC. Past studies have established that splicing of both the K-ras oncogene and proto-oncogene is altered in CRC in favour of K-ras 4B. The present study addressed whether the K-Ras 4A proto-oncoprotein can suppress tumour development in the absence of its oncogenic allele, utilising the ApcMin/+ (Min) mouse that spontaneously develops intestinal tumours that do not harbour K-ras activating mutations, and the K-rastm&#916;4A/tm&#916;4A mouse that can express the K-ras 4B splice variant only. By this means tumorigenesis in the small intestine was compared between ApcMin/+, K-ras+/+ and ApcMin/+, K-rastm&#916;4A/tm&#916;4A mice that can, and cannot, express the K-ras 4A proto-oncoprotein respectively.
Methods:
The relative levels of expression of the K-ras splice variants in normal small intestine and small intestinal tumours were quantified by real-time RT-qPCR analysis. Inbred (C57BL/6) ApcMin/+, K-ras+/+ and ApcMin/+, K-rastm&#916;4A/tm&#916;4A mice were generated and the genotypes confirmed by PCR analysis. Survival of stocks was compared by the Mantel-Haenszel test, and tumour number and area compared by Student's t-test in outwardly healthy mice at approximately 106 and 152 days of age. DNA sequencing of codons 12, 13 and 61 was performed to confirm the intestinal tumours did not harbour a K-ras activating mutation.
Results:
The K-ras 4A transcript accounted for about 50% of K-ras expressed in the small intestine of both wild-type and Min mice. Tumours in the small intestine of Min mice showed increased levels of K-ras 4B transcript expression, but no appreciable change in K-ras 4A transcript levels. No K-ras activating mutations were detected in 27 intestinal tumours derived from Min and compound mutant Min mice. K-Ras 4A deficiency did not affect mouse survival, or tumour number, size or histopathology.
Conclusion:
The K-Ras 4A proto-oncoprotein does not exhibit tumour suppressor activity in the small intestine, even though the K-ras 4A/4B ratio is reduced in adenomas lacking K-ras activating mutations.</description>
			<link>http://www.biomedcentral.com/1471-230X/8/24</link>		
			<dc:creator>Charles E Patek, Mark J Arends, Lorraine Rose, Feijun Luo, Marion Walker, Paul S Devenney, Rachel L Berry, Nicola J Lawrence, Rachel A Ridgway, Owen J Sansom and Martin L Hooper</dc:creator>
			<dc:source>BMC Gastroenterology 2008, 8:24</dc:source>
			<dc:subject>Number of accesses: 344</dc:subject>
			<dc:date>2008-06-13</dc:date>
			<dc:identifier>doi:10.1186/1471-230X-8-24</dc:identifier>
			
			
							
					<prism:publicationName>BMC Gastroenterology</prism:publicationName>
					
			
							
					<prism:issn>1471-230X</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>24</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-06-13</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-230X/8/7">
            
            <title>Gastrointestinal symptoms and motility disorders in patients with systemic scleroderma</title>
			<description>Background:
Studies on gastrointestinal symptoms, dysfunctions, and neurological disorders in systemic scleroderma are lacking so far.
Methods:
Thirty-eight scleroderma patients (34 limited, 4 diffuse), 60 healthy controls and 68 dyspeptic controls were scored for upper and lower gastrointestinal symptoms (dyspepsia, bowel habits), gastric and gallbladder emptying to liquid meal (functional ultrasonography) and small bowel transit (H2-breath test). Autonomic nerve function was assessed by cardiovascular tests.
Results:
The score for dyspepsia (mainly gastric fullness) was greater in scleroderma patients than healthy controls, but lower than dyspeptic controls who had multiple symptoms, instead. Scleroderma patients with dyspepsia had a longer disease duration. Fasting antral area and postprandial antral dilatation were smaller in scleroderma patients than dyspeptic and healthy controls. Gastric emptying was delayed in both scleroderma patients (particularly in those with abnormal dyspeptic score) and dyspeptic controls, who also showed a larger residual area. Despite gallbladder fasting and postprandial volumes were comparable across the three groups, gallbladder refilling appeared delayed in dyspeptic controls and mainly dependent on delayed gastric emptying in scleroderma. Small intestinal transit was also delayed in 74% of scleroderma and 66% of dyspeptic controls. Bowel habits were similar among the three groups. Autonomic neuropathy was not associated with dyspepsia, gastric and gallbladder motility and small intestinal transit.
Conclusion:
In scleroderma patients dyspepsia (mainly gastric fullness), restricted distension of the gastric antrum and diffuse gastrointestinal dysmotility are frequent features. These defects are independent from the occurrence of autonomic neuropathy.</description>
			<link>http://www.biomedcentral.com/1471-230X/8/7</link>		
			<dc:creator>Agostino Di Ciaula, Michele Covelli, Massimo Berardino, David QH Wang, Giovanni Lapadula, Giuseppe Palasciano and Piero Portincasa</dc:creator>
			<dc:source>BMC Gastroenterology 2008, 8:7</dc:source>
			<dc:subject>Number of accesses: 330</dc:subject>
			<dc:date>2008-02-27</dc:date>
			<dc:identifier>doi:10.1186/1471-230X-8-7</dc:identifier>
			
			
							
					<prism:publicationName>BMC Gastroenterology</prism:publicationName>
					
			
							
					<prism:issn>1471-230X</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>7</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-02-27</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
		
	<cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
         <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks"/>
	</cc:License>
</rdf:RDF>
